[BPTH] Bio-Path Holdings, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.3 Change: 0.06 (4.84%)
Ext. hours: Change: 0 (0%)

chart BPTH

Refresh chart

Strongest Trends Summary For BPTH

BPTH is in the medium-term down -87% in 5 months and down -88% below S&P in 6 months. In the long-term down -94% below S&P in 1 year and down -99% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase I study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-7
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.83% ROE-39.54% ROI
Current Ratio21 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-1.41 M Gross Profit
Net Profit-1.37 M Operating Profit-1.38 M Total Assets14.25 M Total Current Assets12.94 M
Total Current Liabilities620 K Total Debt Total Liabilities620 K Total Revenue
Technical Data
High 52 week2.49 Low 52 week0.23 Last close0.23 Last change-0.39%
RSI7.92 Average true range0.06 Beta0.24 Volume147.73 K
Simple moving average 20 days-39.35% Simple moving average 50 days-48.32% Simple moving average 200 days-81.92%
Performance Data
Performance Week-5.18% Performance Month-49.11% Performance Quart-77.33% Performance Half-85.78%
Performance Year-90.04% Performance Year-to-date-88.69% Volatility daily10.53% Volatility weekly23.54%
Volatility monthly48.24% Volatility yearly167.12% Relative Volume350.45% Average Volume322.16 K
New High New Low

News

2019-01-18 12:31:35 | Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

2019-01-18 08:00:00 | Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

2019-01-17 16:07:02 | Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

2019-01-16 08:24:33 | The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

2019-01-14 22:23:31 | Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock

2019-01-14 16:01:00 | Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

2018-12-27 08:49:36 | Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

2018-12-26 09:47:00 | Could Bio-Path Holdings, Inc.’s NASDAQ:BPTH Investor Composition Influence The Stock Price?

2018-12-03 07:22:18 | Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

2018-11-25 09:41:17 | The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

2018-11-15 07:20:33 | Bio-Path: 3Q Earnings Snapshot

2018-11-15 07:00:00 | Bio-Path Holdings Reports Third Quarter 2018 Financial Results

2018-11-08 16:01:00 | Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

2018-11-01 09:05:00 | Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting

2018-10-09 13:11:05 | What does Bio-Path Holdings Inc’s NASDAQ:BPTH Balance Sheet Tell Us About Its Future?

2018-09-25 16:01:00 | Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering

2018-09-21 06:30:00 | Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

2018-08-29 08:00:00 | Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference

2018-08-27 07:30:00 | Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia

2018-08-16 10:26:20 | Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

2018-08-15 07:05:59 | Bio-Path: 2Q Earnings Snapshot

2018-08-15 07:00:00 | Bio-Path Holdings Reports Second Quarter 2018 Financial Results

2018-08-15 06:30:00 | Bio-Path Holdings, Inc. to Host Earnings Call

2018-08-08 09:15:00 | Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

2018-06-26 08:00:00 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. NASDAQ: BPTH

2018-05-16 08:11:09 | With A -19.42% Earnings Drop, Is Bio-Path Holdings Inc’s NASDAQ:BPTH A Concern?

2018-05-16 07:08:30 | Bio-Path: 1Q Earnings Snapshot

2018-05-16 07:00:00 | Bio-Path Holdings Reports First Quarter 2018 Financial Results

2018-05-10 08:00:00 | Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

2018-05-09 08:00:00 | Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

2018-04-18 16:01:00 | Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

2018-04-09 07:20:00 | Wired News – EMA Completed Validation of MAA for Aradigm’s Linhaliq in Non-Cystic Fibrosis Bronchiectasis

2018-04-04 11:15:03 | Bio-Path Leukemia Combo Study Shows Positive Early Data

2018-04-03 12:03:54 | Bio-Path: Why the Biotech Penny Stock Is Skyrocketing Today

2018-04-03 08:35:19 | Benzinga Pro's 5 Stocks To Watch Today

2018-04-03 07:30:00 | Bio-Path Holdings Reports Full Year 2017 Financial Results

2018-04-03 07:15:00 | Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine LDAC for the Treatment of Acute Myeloid Leukemia AML

2018-04-03 06:30:00 | Bio-Path Holdings, Inc. to Host Earnings Call

2018-03-29 08:00:00 | Bio-Path Holdings Announces Publication in The Lancet Haematology

2018-03-27 16:15:00 | Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018

2018-03-15 07:00:00 | Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting

2018-03-06 07:00:00 | Bio-Path Holdings to Present at the 30th Annual ROTH Conference

2018-02-09 07:00:00 | Bio-Path Holdings Announces 1-for-10 Reverse Stock Split

2018-02-05 16:01:00 | Bio-Path Holdings to Present at the BIO CEO & Investor Conference

2018-02-05 08:00:00 | Bio-Path Holdings Appoints Paul Aubert to its Board of Directors

2017-12-29 16:01:00 | Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook

2017-12-15 16:30:00 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. NASDAQ: BPTH

2017-11-13 07:20:00 | Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business

2017-11-10 06:25:10 | Bio-Path Holdings Inc BPTH: How Does It Impact Your Portfolio?

2017-11-09 17:11:38 | Bio-Path reports 3Q loss